Mandatory Guidelines for Federal Workplace Drug Testing Programs--Authorized Testing Panels

Federal Register Extracts

Regulatory Documents

Agency: "Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services (HHS)"

SUMMARY: The Department of Health and Human Services ("HHS" or "Department") herein publishes the panels of Schedule I and II drugs and biomarkers authorized for testing in Federal workplace drug testing programs. The Department has revised the drug testing panels for both urine and oral fluid, and revised required nomenclature for laboratory and Medical Review Officer Reports.

DATES: The authorized drug testing panels and required report nomenclature are effective July 7, 2025.

FOR FURTHER INFORMATION CONTACT: Eugene D. Hayes, Ph.D., MBA, SAMHSA, CSAP, DWP; 5600 Fishers Lane, Room 16N02, Rockville, MD 20857, by telephone [phone] or by email at [email protected].

SUPPLEMENTARY INFORMATION: The drug testing panels in this Notification specify the analytes and cutoffs for Federal agency workplace drug testing specimens and the nomenclature (i.e., analyte names and abbreviations) that must be used to report Federal workplace drug test results, in accordance with Subpart C of the Mandatory Guidelines for Federal Workplace Drug Testing Programs using Urine (UrMG, 88 FR 70768) and the Mandatory Guidelines for Federal Workplace Drug Testing Programs using Oral Fluid (OFMG, 88 FR 70814). Section 3.4 of Subpart C calls upon the Secretary of HHS (Secretary) to "publish the drug and biomarker test analytes and cutoffs (i.e., the 'drug testing panel' and 'biomarker testing panel') for initial and confirmatory drug and biomarker tests in the Federal Register each year," and make them available on the internet at http://www.samhsa.gov/workplace. Section 3.4 of the UrMG and the OFMG also requires HHS-certified laboratories, instrumented initial test facilities (IITFs, urine only), and Medical Review Officers (MROs) to use the nomenclature (i.e., analyte names and abbreviations) published with the drug and biomarker testing panels to report Federal workplace drug test results.

This Federal Register Notification (FRN) contains only the drug testing panel because, to date, HHS has not approved any biomarker tests for use with Federal workplace drug testing specimens. The drug testing panels in Section 3.4 of the UrMG and OFMG will remain in effect until July 7, 2025.

Background

HHS, by the authority of section 503 of Public Law 100-71, 5 U.S.C., and Executive Order 12564, establishes the scientific and technical guidelines...